A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013 Oct; 31(5):1311-20.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Disease-Free Survival
Female
Humans
Leukemia
Male
Middle Aged
Myelodysplastic Syndromes
Phthalazines
Protein Kinase Inhibitors
Pyridines
Receptors, Vascular Endothelial Growth Factor
Treatment Outcome

authors with profiles

Richard A. Larson
Olatoyosi Odenike